Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
You may also be interested in...
J&J/Merck Bolsters Heartburn Lineup With Maximum Strength Pepcid AC
New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck
Prilosec OTC Has Retailers Staying Up Late; “BurnTown” Preview Underway
Wal-Mart is shipping "pre-awareness" promotional kits for Procter & Gamble's Prilosec OTC (omeprazole) to its stores in anticipation of the heartburn prevention drug's Sept. 15 launch
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.